Navigation Links
Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™
Date:8/31/2011

arallel treatment groupRouteTopicalFrequencySingle application Dose Levels0.37% w/v or 0.74% w/vNumber of Subjects132Subject Selection Criteria

  • 2 years of age or older
  • Good health
  • Has an active head lice infestation as determined by an experienced evaluator

  • Primary End Points

  • Proportion of all subjects who are lice free at all follow-up visits through the Day 14 visit

  • Secondary End Points

  • Safety and tolerability of Ha44 Gel
  • Proportion of index subjects who are lice free at all follow-up visits through the Day 14 visit
  • Proportion of all subjects who are lice free at each follow-up study visit (Day 1, 7, 14)
  • To evaluate the pharmacokinetics of Ha44 Gel in a subset of children 2-12 years of age and adults ≥ 18 years of age

  • Trial Location2 sites in USAExpected Duration of the TrialThe trial is expected to in completed in 9 monthsCommercial PartnersNoneSponsorHatchtech Pty LtdAbout HatchtechHatchtech Pty Ltd is a venture-backed specialty pharmaceutical product company that is developing technology for the control of invertebrate pests. The company's investors include, GBS Venture Partners, Queensland Biotechnology Fund, Uniseed, University of Melbourne Endowment Trust, Westscheme and OneVentures Innovation Fund. The OneVentures Innovation Fund is supported by the Australian Government through the IIF program. The IIF is an Australian Government venture capital initiative that has supported Hatchtech

    The company's lead product is DeOvo™, a class leading head lice control agent that aims to overcome the frustrating, costly and inconvenient cycles of re-treatment experienced currently by children and their parents.

    Hatchtech
    '/>"/>

    SOURCE Hatchtech Pty Ltd
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
    4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
    5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
    7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
    8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
    9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
    10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
    11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers ... technologies must be able to protect their ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... of the Medical Device Industry, it steadfastly ... sectors of cases involving IP infringement. This ...
    (Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ... cells. VSRNAs are of molecular size less than 10 ...
    (Date:1/15/2014)... 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ... growth of these markets. The European ...
    Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
    ... Therapeutics (NYSE Amex: CXM ) today provided an ... Pharmaceuticals, business assets in connection with a proposed asset purchase ... on June 27, 2011, the completion of such an asset ... of the bankruptcy court.  In an effort to expedite the ...
    ... Corporation,s (NYSE: BSX ) Board of Directors ... up to $1.0 billion of its common stock and ... existing share repurchase program. "This repurchase program ... long-term business prospects, earnings growth potential and our ability ...
    Cached Medicine Technology:Cardium Reports on Transdel Transaction 2Cardium Reports on Transdel Transaction 3Cardium Reports on Transdel Transaction 4Boston Scientific Announces $1.0B Share Repurchase Program 2Boston Scientific Announces $1.0B Share Repurchase Program 3
    (Date:4/14/2014)... John DeLuca, PhD, and Yael Goverover, PhD, OT, have ... persons with multiple sclerosis (MS) perform everyday life tasks. ... Measure Everyday Life Functional Activity in Multiple Sclerosis" provides ... senior VP of Research & Training at Kessler Foundation. ... is a visiting scientist at Kessler Foundation. She was ...
    (Date:4/14/2014)... the answer to one open-ended question predicted the teenagers, offending ... think you,ll live?", According to the study, having little hope ... Piquero said the study found those who don,t view a ... rates and commit more serious offenses, while those who believe ... less., "In a lot of distressed communities and for a ...
    (Date:4/14/2014)... a molecule that is a probable driving force in ... an important target for colorectal cancer treatment and a ... microRNA-135b (miR-135b) in two animal models and human tumors ... and was led by researchers at The Ohio State ... Hospital and Richard J. Solove Research Institute (OSUCCC ...
    (Date:4/14/2014)... Depression can hit young fathers hard -- with symptoms increasing ... children,s lives, a new Northwestern Medicine study has found. , ... first five years of fatherhood for these young men, who ... whom lived in the same home as their children. The ... journal Pediatrics . , This study is the first ...
    (Date:4/14/2014)... WASHINGTON, April 14In dense, urban centers around the world, ... streets surrounded by tall buildings that block sunlight. And ... are jammed closer together, the darkness will only spread. ... developed a corrugated, translucent panel that redirects sunlight onto ... rooftops and hung over the edge at an angle, ...
    Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
    ... to Accelerate Sales of the New, Fully Nano-Encapsulated Liquid Vitamin, ... and COLUMBUS, Ohio, June 23 livethesource(TM) announced ... has joined the company,s distribution network to help ... its breakthrough technology, daily source(TM) is a complete ...
    ... suggests a direct link between smoking and brain damage will ... of Neurochemistry . Researchers, led by Debapriya Ghosh and Dr ... have found that a compound in tobacco provokes white blood ... leading to severe neurological damage. The research centers ...
    ... Each year hospital operating rooms face increasingly difficult ... more demanding. Saint Vincent Health Center (SVHC) in ... provided by Eclipsys Corp. and powered by Surgical Information ... and national averages for quality measures. , , ...
    ... Derma Sciences, Inc. (OTC ... products, announced today that it has begun shipping BIOGUARD(TM) ... that it has been awarded reimbursement codes for the ... BIOGUARD will offer surgeons, wound care clinicians, infection ...
    ... WASHINGTON, June 23 A study released earlier this month ... Ohio University found that medical bills are involved ... 50 percent just six years ago. Additionally, more than 75 ... overwhelmed by the out-of-pocket expenses. In the wake of these ...
    ... Center offers more services to autistic community with the help ... Judson Center ( www.judsoncenter.org ), a comprehensive ... of individuals and families, today opens the newly-constructed Autism Center ... headquarters. Judson Center employees, autism advocates and families as ...
    Cached Medicine News:Health News:Internationally-Renowned Health and Wellness Authority Joins livethesource(TM) as a Master Distributor 2Health News:Internationally-Renowned Health and Wellness Authority Joins livethesource(TM) as a Master Distributor 3Health News:New research discovers link between smoking and brain damage 2Health News:Saint Vincent Health Center Ensures Regulatory Compliance with SIS 2Health News:Saint Vincent Health Center Ensures Regulatory Compliance with SIS 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 2Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 4Health News:The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 2Health News:The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 3Health News:Judson Center Celebrates Grand Opening of its New Autism Center 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: